Cutia Therapeutics (HKG:2487)

Market Cap	259.35M -90.1%
Revenue (ttm)	383.95M +32.9%
Net Income	-324.64M
EPS	-0.92
Shares Out	373.17M
PE Ratio	n/a
Forward PE	19.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,000
Open	0.6850
Previous Close	0.6800
Day's Range	0.6800 - 0.7450
52-Week Range	0.6000 - 7.5000
Beta	0.78
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Cutia Therapeutics

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 268
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2487

Financial Performance

In 2025, Cutia Therapeutics's revenue was 336.15 million, an increase of 20.22% compared to the previous year's 279.62 million. Losses were -340.19 million, -21.58% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error